Status:

COMPLETED

The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy.

Lead Sponsor:

Radboud University Medical Center

Collaborating Sponsors:

GlaxoSmithKline

Conditions:

Ischemia-Reperfusion Injury

The Metabolic Syndrome

Eligibility:

All Genders

20-70 years

Phase:

PHASE2

Brief Summary

Cardiovascular disease is the leading cause of death in diabetic patients due to both a high event rate and a worse outcome. A pharmacological intervention that reduces ischemia-reperfusion-injury wou...

Detailed Description

Rationale: Cardiovascular disease is the leading cause of death in diabetic patients due to both a high event rate and a worse outcome. A pharmacological intervention that reduces ischemia-reperfusion...

Eligibility Criteria

Inclusion

  • At least 3 features of the metabolic syndrome (AHA/NHLBI).
  • Willing and able to provide a signed and dated written informed consent.
  • Men or postmenopausal women aged between 20 and 70 years.

Exclusion

  • Fasting glucose \> 7,0 mmol/L or the use of hypoglycaemic agents. If fasting plasma glucose is between 6.1 and 7,0 mmol/L, an oral 75 g glucose test will be performed to exclude diabetes mellitus.
  • Exposure to a PPAR-g agonist during the last 4 months or a documented significant hypersensitivity to a PPAR-g agonist.
  • Participant in another study.
  • Angina or heart failure (NYHA I-IV).
  • Clinically significant liver disease (3 times the upper normal limit of ALAT, ASAT, AF, γGT or LDH)
  • Clinically significant anemia (male Hb \< 6,9 mmol/L, female \< 6,25 mmol/L)
  • Creatinin clearance \< 40 mL/min
  • Alcohol or drug abuse.
  • Any physical inability to perform the exercise protocol.
  • Administration of any radio pharmacon for research purposes in the previous 5 years.

Key Trial Info

Start Date :

April 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2008

Estimated Enrollment :

13 Patients enrolled

Trial Details

Trial ID

NCT00405015

Start Date

April 1 2007

End Date

October 1 2008

Last Update

August 24 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Clinical research Center Nijmegen

Nijmegen, Netherlands, 6500 HB